Stranded Technologies Podcast · Infinita City

Ep. 104: Ruxandra Teslo: Clinical Trials, Drug Innovation, and the Bottleneck to Biotech Abundance

February 20, 2026·1 hr 3 min·4 clips

Teslo argues that small human trials are part of scientific discovery, not just a final approval gate.

The conversation starts with abundance. The host puts biotech inside a wider frontier-tech argument: longer lives, clean energy, transparent markets, robots, and AI all seem slower than promised. The show’s frame is over-regulation, and clinical trials are the test case where the argument gets concrete. Ruxandra is introduced as a genomics PhD blogger, Substack writer, and writer for the Clinical Trial Abundance Project, so the episode stays close to practical bottlenecks. The main one is measurement. Companies can only test, fund, and chase what they can show works, and clinical trials make that burden expensive. Surrogate endpoints should be the escape hatch. They can support approval, and sometimes full approval, when regulators accept them as good enough measures. The catch is that validation is slow, hard to fund, and not especially rewarding. Better biomarkers may help everyone, but they are not easy to sell as products. That leaves a strange setup: academia keeps producing biomarker research, many promising measures never become regulatory endpoints, and older weaker endpoints stick around because pulling them away could freeze drug development. That is the distorted equilibrium Ruxandra keeps circling. The market invests around what can be measured and approved, not necessarily around the full range of useful therapies. One route is to get much better at developing surrogate endpoints. Another is a safety-first model, where drugs reach the market after safety is established and usefulness gets sorted through use and later evidence. That second route is not hand-wavy. It immediately raises the hard stuff: insurance reimbursement, post-approval measurement, and who pays when efficacy partly moves outside the premarket trial gate. The close widens out again. Ruxandra argues the field needs more people defining the problems because the work cuts across law, interviews, institutional detail, and technical evidence. China comes up as a reason this may matter more soon.

As heard by us

A focused look at how clinical trial rules and incentives shape biotech innovation.

The episode frames clinical trials as part of a larger biotech bottleneck, where approval rules, surrogate endpoints, and incentives all shape what gets developed.

Read the full review in PlayNext →

Why you'd press play

If you want a thoughtful look at why clinical trials and efficacy measurement can slow biotech progress, start here.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Stranded Technologies Podcast